FDA Approves Topical Treatment for Molluscum Contagiosum
MONDAY, July 24, 2023 (HealthDay News) — The U.S. Food and Drug Administration has approved the topical solution Ycanth (cantharidin) for the treatment of molluscum contagiosum (molluscum) in adult and pediatric patients (aged 2 years and older).Ycan…
Learn MoreUn fármaco experimental para el Alzheimer ralentiza el declive del pensamiento en un ensayo avanzado
LUNES, 17 de julio de 2023 (HealthDay News) — Parece que otro medicamento experimental que busca ralentizar el daño del Alzheimer está a punto de unirse a un creciente arsenal de nuevos tratamientos para esta enfermedad que roba la memoria. En una in…
Learn MoreFDA Approves New Drug to Protect Against RSV in Infants
MONDAY, July 17, 2023 (HealthDay Now) — Parents now have a new long-acting drug to protect their children against respiratory syncytial virus (RSV), a common infection that hospitalizes as many as 3 percent of children younger than 1 year in the Unit…
Learn MoreExperimental Alzheimer’s Drug Slows Thinking Declines in Late-Stage Trial
MONDAY, July 17, 2023 (HealthDay News) — Another experimental drug meant to slow the damage of Alzheimer’s appears poised to join a growing arsenal of new treatments for this memory-robbing disease.In research published online Monday in the Journal o…
Learn MoreFDA Approves First Over-the-Counter Birth Control Pill
THURSDAY, July 13, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Thursday approved the nation’s first over-the-counter birth control pill, a move that will likely pave the way for far greater access to contraception for Americans.W…
Learn MoreTherapeutic Value of Drugs Lower for Supplemental Versus First Indications
FRIDAY, July 7, 2023 (HealthDay News) — For drugs approved in the United States and Europe, the therapeutic value of supplemental indications is lower than for first indications, according to a study published online July 5 in The BMJ.Kerstin N. Voki…
Learn MoreFDA Gives Full Approval to Alzheimer Disease Drug Leqembi
THURSDAY, July 6, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Thursday gave full approval to the Alzheimer disease drug Leqembi (lecanemab-irmb), clearing the way for insurance coverage of the pricey drug.”Today’s action is the f…
Learn MoreFDA Gives Full Approval to Alzheimer’s Drug Leqembi
THURSDAY, July 6, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Thursday gave full approval to the Alzheimer’s drug Leqembi, clearing the way for insurance coverage of the pricey drug.“The full FDA approval will open the floodgates…
Learn MoreFDA Approves Subcutaneous Vyvgart Hytrulo for Generalized Myasthenia Gravis
TUESDAY, June 27, 2023 (HealthDay News) — The U.S. Food and Drug Administration has approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) subcutaneous injections for the treatment of generalized myasthenia gravis (gMG) in adult patients…
Learn MoreFDA Approves Litfulo for Teens, Adults With Alopecia Areata
TUESDAY, June 27, 2023 (HealthDay News) — The U.S. Food and Drug Administration has approved Litfulo (ritlecitinib) for adults and adolescents aged 12 years and older with severe alopecia areata at a recommended dose of 50 mg. Approval of Litfulo was…
Learn More